These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21594716)

  • 1. Targeted delivery to neuroblastoma of novel siRNA-anti-GD2-liposomes prepared by dual asymmetric centrifugation and sterol-based post-insertion method.
    Adrian JE; Wolf A; Steinbach A; Rössler J; Süss R
    Pharm Res; 2011 Sep; 28(9):2261-72. PubMed ID: 21594716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of small amounts of sterile siRNA-liposomes with high entrapping efficiency by dual asymmetric centrifugation (DAC).
    Hirsch M; Ziroli V; Helm M; Massing U
    J Control Release; 2009 Apr; 135(1):80-8. PubMed ID: 19124051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
    Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
    Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma.
    Shen M; Gong F; Pang P; Zhu K; Meng X; Wu C; Wang J; Shan H; Shuai X
    Int J Nanomedicine; 2012; 7():3319-32. PubMed ID: 22802690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.
    Pagnan G; Stuart DD; Pastorino F; Raffaghello L; Montaldo PG; Allen TM; Calabretta B; Ponzoni M
    J Natl Cancer Inst; 2000 Feb; 92(3):253-61. PubMed ID: 10655443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S; Modak S
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
    Ohta S; Igarashi S; Honda A; Sato S; Hanai N
    Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
    Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
    Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
    Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
    Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.
    Brown BS; Patanam T; Mobli K; Celia C; Zage PE; Bean AJ; Tasciotti E
    Cancer Biol Ther; 2014 Jul; 15(7):851-61. PubMed ID: 24755919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of high-risk neuroblastoma with anti-GD2 antibodies.
    Castel V; Segura V; Cañete A
    Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.
    Brignole C; Pagnan G; Marimpietri D; Cosimo E; Allen TM; Ponzoni M; Pastorino F
    Cancer Lett; 2003 Jul; 197(1-2):231-5. PubMed ID: 12880987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.
    Monterrubio C; Paco S; Olaciregui NG; Pascual-Pasto G; Vila-Ubach M; Cuadrado-Vilanova M; Ferrandiz MM; Castillo-Ecija H; Glisoni R; Kuplennik N; Jungbluth A; de Torres C; Lavarino C; Cheung NKV; Mora J; Sosnik A; Carcaboso AM
    J Control Release; 2017 Jun; 255():108-119. PubMed ID: 28412222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
    Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
    Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.